Circular RNA of vimentin expression as a valuable predictor for acute myeloid leukemia development and prognosis

J Cell Physiol. 2019 Apr;234(4):3711-3719. doi: 10.1002/jcp.27145. Epub 2018 Aug 28.

Abstract

The focus of this study was to investigate the expression status of Circ-vimentin (VIM) and further analyze its pathogenesis and clinical significance in acute myeloid leukemia (AML) patients. Real-time quantitative polymerase chain reaction was carried on Circ-VIM in 113 AML patients and 42 healthy controls. Circ-VIM was significantly upregulated in AML compared with control and was positively correlated with white blood cells (WBC) count. Receiver operating characteristic curve analysis indicated that the performance of Circ-VIM expression could serve as a promising biomarker for differentiating AML patients from controls. Significant correlations of Circ-VIM expression were found with WBC and French-American-British classifications. Survival analyses further showed that over-expressed Circ-VIM were associated with markedly shorter overall survival (OS) and leukemia-free survival (LFS) in whole-cohort AML, nonacute promyelocytic leukemia AML and cytogenetically normal-AML patients. Multivariate analysis also disclosed that Circ-VIM over-expression was an independent poor prognostic factor for OS and LFS in AML patients. Remarkably, Pearson correlation analysis evidenced that the expression of Circ-VIM was positively correlated with VIM expression in all AML patients. These results indicated that overexpression Circ-VIM could serve as a significant biomarker.

Keywords: Circ-VIM; acute myeloid leukemia; circular RNA; tumor marker.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / genetics*
  • Case-Control Studies
  • Child
  • Disease Progression
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / pathology
  • Leukemia, Myeloid, Acute / therapy
  • Male
  • Middle Aged
  • Progression-Free Survival
  • RNA, Circular / genetics*
  • RNA, Neoplasm / genetics*
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Up-Regulation
  • Vimentin / genetics*
  • Young Adult

Substances

  • Biomarkers, Tumor
  • RNA, Circular
  • RNA, Neoplasm
  • VIM protein, human
  • Vimentin